https://treadwelltx.com/wp-content/uploads/logo.png00Vladimir Vinogradovhttps://treadwelltx.com/wp-content/uploads/logo.pngVladimir Vinogradov2022-06-13 19:48:272022-06-13 19:48:27Treadwell Announces Initiation of Patient Dosing in TWT-203, a Phase 1b/2 study of TTK Inhibitor, CFI-402257, in Patients with ER+/Her2- Breast cancer
https://treadwelltx.com/wp-content/uploads/logo.png00Vladimir Vinogradovhttps://treadwelltx.com/wp-content/uploads/logo.pngVladimir Vinogradov2022-04-26 16:57:322022-04-26 16:57:32Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia
https://treadwelltx.com/wp-content/uploads/logo.png00Vladimir Vinogradovhttps://treadwelltx.com/wp-content/uploads/logo.pngVladimir Vinogradov2022-04-10 14:59:402022-04-11 10:56:27Treadwell Therapeutics and University Health Network Sign Licensing Agreement for pre-clinical biologic and small molecule assets
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2021-12-08 08:00:222022-03-14 14:33:46Treadwell Therapeutics Announces A Presentation at the 2021 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2021-11-30 08:00:322022-03-14 14:36:51Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of TTK inhibitor, CFI-402257
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2021-11-18 08:00:492022-03-14 14:42:22Treadwell Therapeutics Announces The Closing of a $91 Million Series B Financing
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2021-11-12 08:00:262022-03-11 15:23:55Treadwell Therapeutics Announces a Presentation at the 2021 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor
https://treadwelltx.com/wp-content/uploads/logo.png00Vladimir Vinogradovhttps://treadwelltx.com/wp-content/uploads/logo.pngVladimir Vinogradov2022-06-13 19:48:272022-06-13 19:48:27Treadwell Announces Initiation of Patient Dosing in TWT-203, a Phase 1b/2 study of TTK Inhibitor, CFI-402257, in Patients with ER+/Her2- Breast cancer
https://treadwelltx.com/wp-content/uploads/logo.png00Vladimir Vinogradovhttps://treadwelltx.com/wp-content/uploads/logo.pngVladimir Vinogradov2022-04-26 16:57:322022-04-26 16:57:32Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia
https://treadwelltx.com/wp-content/uploads/logo.png00Vladimir Vinogradovhttps://treadwelltx.com/wp-content/uploads/logo.pngVladimir Vinogradov2022-04-10 14:59:402022-04-11 10:56:27Treadwell Therapeutics and University Health Network Sign Licensing Agreement for pre-clinical biologic and small molecule assets
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2021-12-08 08:00:222022-03-14 14:33:46Treadwell Therapeutics Announces A Presentation at the 2021 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2021-11-30 08:00:322022-03-14 14:36:51Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of TTK inhibitor, CFI-402257
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2021-11-18 08:00:492022-03-14 14:42:22Treadwell Therapeutics Announces The Closing of a $91 Million Series B Financing
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2021-11-12 08:00:262022-03-11 15:23:55Treadwell Therapeutics Announces a Presentation at the 2021 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2021-10-15 08:00:372022-03-11 15:26:22Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a Novel TCR-Based T Cell Therapy Company and TIO Bioventures Portfolio Company
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2021-04-30 08:00:202022-03-11 15:27:18Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2021-02-10 08:00:252022-03-14 15:16:30Treadwell Expands Operations with New Local Footprint at Toronto’s University Health Network
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2021-12-07 08:00:492022-03-11 16:54:56Treadwell Announces Two Presentations at the 2020 ASH Annual Meeting Featuring Clinical Trial Updates on Lead Product Candidate, CFI-400945
https://treadwelltx.com/wp-content/uploads/logo.png00Emily Henneshttps://treadwelltx.com/wp-content/uploads/logo.pngEmily Hennes2020-10-19 08:00:482022-03-14 15:20:46Treadwell Announces Initiation of New Clinical Trial of CFI-400945 in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)